Description

Product Description

Bremelanotide (PT-141) is a synthetic peptide analogue of ?-melanocyte-stimulating hormone (?-MSH), designed to activate melanocortin receptors (MCRs) in the central nervous system. Structurally derived from ?-MSH, Bremelanotide retains receptor selectivity and enhanced stability, making it an ideal research compound for studying sexual behavior, neuroendocrine regulation, and related CNS pathways.

The compound primarily targets the medial preoptic area (mPOA) and other hypothalamic and limbic regions, which are critical nodes in the neural circuits controlling sexual motivation, arousal, and behavior. By mimicking the effects of ?-MSH, Bremelanotide can modulate melanocortin receptors, leading to increased neural activity in key sexual behavior centers without affecting peripheral melanogenesis to a significant degree at research-relevant doses.

Bremelanotide exhibits several advantages for preclinical research:

• High Purity: ?99.43% verified by HPLC, ensuring reproducible experimental outcomes.

• GMP-compliant Production: Provides consistent peptide quality suitable for both wholesale and retail laboratory applications.

• Central Nervous System Targeting: Preferentially activates mPOA and limbic pathways for behavioral studies.

• Peptide Stability: Resistant to proteolytic degradation under proper storage conditions.

Researchers utilize Bremelanotide in rodent, primate, and in vitro neurophysiological models to explore sexual behavior regulation, receptor pharmacology, and CNS pathways modulated by melanocortin peptides. Its use in hypoactive sexual desire disorder (HSDD) research provides insights into potential neuroendocrine therapeutic strategies.

Additionally, Bremelanotide is compared to other melanocortin analogues for efficacy, receptor specificity, and stability, allowing systematic exploration of structure-activity relationships and neurobehavioral outcomes in preclinical studies. The salt form of the peptide enhances solubility for aqueous-based administration, ensuring consistent dosing and experimental reproducibility.

Product Specifications

Bremelanotide’s high purity, combined with GMP-grade manufacturing, guarantees reliable outcomes across neurobehavioral assays and pharmacological studies. Its solubility in aqueous solutions facilitates precise dosing in animal models and in vitro neuronal preparations. The peptide maintains structural integrity during standard storage, ensuring consistency across repeated experimental runs.

Mechanism of Action & Research Applications

Bremelanotide functions as a selective melanocortin receptor agonist, primarily targeting MCR subtypes in the central nervous system. Its activity is concentrated in the medial preoptic area (mPOA), hypothalamus, and limbic system, key regions responsible for sexual motivation and arousal.

Molecular Mechanism:

• Binds to MCR1, MCR3, and MCR4 in neuronal tissue.

• Activates intracellular cAMP signaling pathways.

• Enhances neurotransmitter release and synaptic activity in sexual behavior circuits.

Research Applications:

• Hypoactive Sexual Desire Disorders (HSDD): Bremelanotide is used to study neural modulation of sexual desire and potential therapeutic interventions.

• CNS Sexual Function Research: Investigates neuronal pathways, receptor pharmacology, and melanocortin system modulation.

• Neurobehavioral Studies: Examines mating behavior, arousal, and motivational states in rodent and primate models.

• Combination Research: Used with other neuropeptides or small molecules to study synergistic effects on CNS circuits.

• Translational Research Potential: Provides insights into the development of neuroactive compounds targeting sexual dysfunctions.

Preclinical studies show that Bremelanotide modulates neuronal firing rates and synaptic plasticity within sexual behavior centers, producing measurable behavioral changes in a dose-dependent manner. These studies enhance understanding of the molecular and cellular basis of sexual motivation, enabling the evaluation of potential pharmacological therapies for HSDD.

Bremelanotide also serves as a benchmark molecule in CNS melanocortin receptor research, allowing systematic investigation of receptor subtype contributions to behavior and neuroendocrine regulation.

Side Effects (For Reference in Research Models)

Experimental studies report several effects associated with Bremelanotide administration:

• Behavioral Changes: Increased sexual motivation and activity in rodent models; dose-dependent effects.

• Physiological Effects: Minor transient increases in blood pressure and heart rate in animal models at high doses.

• Injection Site Reactions: Occasional mild local irritation observed with parenteral administration.

• CNS Considerations: Overstimulation at supraphysiological doses may affect sleep-wake cycles and general arousal.

Experimental Considerations:

• Dose titration is critical to avoid overstimulation and confounding behavioral data.

• Ensure consistent peptide preparation to maintain reproducibility.

• Repeated freeze-thaw cycles may reduce peptide efficacy.

Bremelanotide is intended strictly for laboratory research. Its effects in preclinical models provide a reference for behavioral and physiological outcomes, but human clinical safety cannot be inferred.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Bremelanotide CAS 189691-06-3

• PT-141 GMP supplier

• Bremelanotide peptide analogue

• Research use only Bremelanotide

• CNS melanocortin receptor agonist peptide

• Buy Bremelanotide for research

• Hypoactive sexual desire disorder research

• Preclinical sexual behavior studies

• Synthetic ?-MSH analogue

• Bremelanotide rodent and primate models